<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36249044</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2234-943X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab.</ArticleTitle><Pagination><StartPage>945060</StartPage><MedlinePgn>945060</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">945060</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2022.945060</ELocationID><Abstract><AbstractText>Post-coronavirus disease 2019 (post-COVID-19) condition, previously referred to as long COVID, includes a post-acute syndrome defined by the presence of non-specific symptoms occurring usually 3&#xa0;months from the onset of the acute phase and lasting at least 2&#xa0;months. Patients with chronic lymphocytic leukemia (CLL) represent a high-risk population for COVID-19. Moreover, the response to SARS-CoV-2 vaccination is often absent or inadequate. The introduction of monoclonal antibodies (mAbs) in the treatment landscape of COVID-19 allowed to reduce hospitalization and mortality in mild-moderate SARS-CoV-2 infection, but limited data are available in hematological patients. We here report the effective use of casirivimab/imdevimab (CI) in the treatment of two CLL patients with persistent infection and post-COVID-19 condition. Full genome sequencing of viral RNA from nasopharyngeal swabs was performed at the time of COVID-19 diagnosis and before the administration of CI. Both patients experienced persistent SARS-CoV-2 infection with no seroconversion for 8 and 7&#xa0;months, respectively, associated with COVID symptoms. In both cases after the infusion of CI, we observed a rapid negativization of the nasal swabs, the resolution of post-COVID-19 condition, and the development of both the IgG against the trimeric spike protein and the receptor-binding domain (RBD) of the spike protein. The analysis of the viral genome in the period elapsed from the time of COVID-19 diagnosis and the administration of mAbs showed the development of new mutations, especially in the <i>S</i> gene. The genome variations observed during the time suggest a role of persistent SARS-CoV-2 infection as a possible source for the development of viral variants. The effects observed in these two patients appeared strongly related to passive immunity conferred by CI treatment permitting SARS-CoV-2 clearance and resolution of post-COVID-19 condition. On these grounds, passive anti-SARS-CoV-2 antibody treatment may represent as a possible therapeutic option in some patients with persistent SARS-CoV-2 infection.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Ballotta, Simonetti, D&#x2019;Agaro, Segat, Koncan, Martinez-Orellana, Dattola, Orsini, Marcello, Dal Monego, Licastro, Misin, Mohamed, Sbis&#xe0;, Lucchini, De Sabbata, Zaja and Luzzati.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballotta</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Dipartimento Clinico di Scienze Mediche, Chirurgiche e della Salute, Universit&#xe0; degli Studi di Trieste, Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit&#xe0; Complessa Operativa (UCO) Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonetti</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Struttura Complessa (SC) Malattie Infettive, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Agaro</LastName><ForeName>Pierlanfranco</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dipartimento Clinico di Scienze Mediche, Chirurgiche e della Salute, Universit&#xe0; degli Studi di Trieste, Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit&#xe0; Complessa Operativa (UCO) Igiene e Sanit&#xe0; Pubblica, Azienda Sanitaria Universitaria Integrata Giuliano Isontina, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segat</LastName><ForeName>Ludovica</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit&#xe0; Complessa Operativa (UCO) Igiene e Sanit&#xe0; Pubblica, Azienda Sanitaria Universitaria Integrata Giuliano Isontina, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koncan</LastName><ForeName>Raffaella</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dipartimento Clinico di Scienze Mediche, Chirurgiche e della Salute, Universit&#xe0; degli Studi di Trieste, Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit&#xe0; Complessa Operativa (UCO) Igiene e Sanit&#xe0; Pubblica, Azienda Sanitaria Universitaria Integrata Giuliano Isontina, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Orellana</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Virology, International Centre for Genetic Engineering and Biotechnology (ICGEB), AREA Science Park, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dattola</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Virology, International Centre for Genetic Engineering and Biotechnology (ICGEB), AREA Science Park, Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Life Sciences, Universit&#xe0; degli Studi di Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orsini</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Virology, International Centre for Genetic Engineering and Biotechnology (ICGEB), AREA Science Park, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcello</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Virology, International Centre for Genetic Engineering and Biotechnology (ICGEB), AREA Science Park, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dal Monego</LastName><ForeName>Simeone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biomedicine, AREA Science Park, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Licastro</LastName><ForeName>Danilo</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biomedicine, AREA Science Park, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misin</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Struttura Complessa (SC) Malattie Infettive, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohamed</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit&#xe0; Complessa Operativa (UCO) Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sbis&#xe0;</LastName><ForeName>Eugenio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unit&#xe0; Complessa Operativa (UCO) Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucchini</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unit&#xe0; Complessa Operativa (UCO) Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Sabbata</LastName><ForeName>Giovanni Maria</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Unit&#xe0; Complessa Operativa (UCO) Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaja</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dipartimento Clinico di Scienze Mediche, Chirurgiche e della Salute, Universit&#xe0; degli Studi di Trieste, Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit&#xe0; Complessa Operativa (UCO) Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luzzati</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dipartimento Clinico di Scienze Mediche, Chirurgiche e della Salute, Universit&#xe0; degli Studi di Trieste, Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Struttura Complessa (SC) Malattie Infettive, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID - 19</Keyword><Keyword MajorTopicYN="N">casirivimab/imdevimab</Keyword><Keyword MajorTopicYN="N">chronic lymphocyte leukemia</Keyword><Keyword MajorTopicYN="N">monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">post COVID-19 condition</Keyword></KeywordList><CoiStatement>Dr. LB received honoraria for giving lectures at medical meetings from AbbVie. Dr. FZ received advisory board fees or honoraria for giving lectures at medical meetings from Roche, Celgene, Janssen, Sandoz, Gilead, Novartis, AbbVie, Amgen, Sobi, Argenx, Grifols, Takeda, and BeiGene. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>17</Day><Hour>5</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36249044</ArticleId><ArticleId IdType="pmc">PMC9561900</ArticleId><ArticleId IdType="doi">10.3389/fonc.2022.945060</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. . 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet (2021) 397(10270):220&#x2013;32. doi: 10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO . A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 . Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition Clinical_case_definition-2021.1 (Accessed 3 March 2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Maschmeyer G, De Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A, et al. . Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European conference on infections in leukemia (ECIL). Leukemia (2019) 33(4):844&#x2013;62. doi:&#xa0;10.1038/s41375-019-0388-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-019-0388-x</ArticleId><ArticleId IdType="pmc">PMC6484704</ArticleId><ArticleId IdType="pubmed">30700842</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. . Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients. Blood (2020) 136(25):2881&#x2013;92. doi: 10.1182/blood.2020008824</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008824</ArticleId><ArticleId IdType="pmc">PMC7746126</ArticleId><ArticleId IdType="pubmed">33113551</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, et al. . Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncol (2021) 22(12):1669&#x2013;80. doi: 10.1016/S1470-2045(21)00573-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(21)00573-8</ArticleId><ArticleId IdType="pmc">PMC8565932</ArticleId><ArticleId IdType="pubmed">34741822</ArticleId></ArticleIdList></Reference><Reference><Citation>Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. . Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood (2021) 137(23):3165&#x2013;73. doi: 10.1182/blood.2021011568</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021011568</ArticleId><ArticleId IdType="pmc">PMC8061088</ArticleId><ArticleId IdType="pubmed">33861303</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. . Hydroxychloroquine with or without azithromycin in mild-to-Moderate covid-19. N Engl J Med (2020) 383(21):2041&#x2013;52. doi: 10.1056/NEJMoa2019014</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2019014</ArticleId><ArticleId IdType="pmc">PMC7397242</ArticleId><ArticleId IdType="pubmed">32706953</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. . Remdesivir for the treatment of covid-19 - final report. N Engl J Med (2020) 383(19):1813&#x2013;26. doi: 10.1056/NEJMoa2007764</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. . Tocilizumab in patients hospitalized with covid-19 pneumonia. N Engl J Med (2021) 384(1):20&#x2013;30. doi: 10.1056/NEJMoa2030340</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2030340</ArticleId><ArticleId IdType="pmc">PMC7781101</ArticleId><ArticleId IdType="pubmed">33332779</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, et al. . Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: Initial three-month experience. medRxiv [Preprint]. (2020) 12:2020.08.12.20169359. doi: 10.1101/2020.08.12.20169359</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.08.12.20169359</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. . Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med (2021) 385(21):1941&#x2013;50. doi: 10.1056/NEJMoa2107934</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107934</ArticleId><ArticleId IdType="pubmed">34706189</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, et al. . Bamlanivimab plus etesevimab in mild or moderate covid-19. N Engl J Med (2021) 385(15):1382&#x2013;92. doi: 10.1056/NEJMoa2102685</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102685</ArticleId><ArticleId IdType="pmc">PMC8314785</ArticleId><ArticleId IdType="pubmed">34260849</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. . REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N Engl J Med (2021) 384(3):238&#x2013;51. doi: 10.1056/NEJMoa2035002</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035002</ArticleId><ArticleId IdType="pmc">PMC7781102</ArticleId><ArticleId IdType="pubmed">33332778</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabascall CX, Lou BX, Navetta-Modrov B, Hahn SS. Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab. BMJ Case Rep (2021) 14(8):e243469. doi: 10.1136/bcr-2021-243469</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2021-243469</ArticleId><ArticleId IdType="pmc">PMC8336168</ArticleId><ArticleId IdType="pubmed">34344651</ArticleId></ArticleIdList></Reference><Reference><Citation>Drouin AC, Theberge MW, Liu SY, Smither AR, Flaherty SM, Zeller M, et al. . Successful clearance of 300 day SARS-CoV-2 infection in a subject with b-cell depletion associated prolonged (B-DEAP) COVID by REGEN-COV anti-spike monoclonal antibody cocktail. Viruses (2021) 13(7):1202. doi: 10.3390/v13071202</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13071202</ArticleId><ArticleId IdType="pmc">PMC8310246</ArticleId><ArticleId IdType="pubmed">34201591</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda H, Mori Y, Chiba A, Bai J, Murayama G, Matsushita Y, et al. . Resolution of one-year persisting COVID-19 pneumonia and development of immune thrombocytopenia in a follicular lymphoma patient with preceding rituximab maintenance therapy: A follow-up report and literature review of cases with prolonged infections. Clin Lymphoma Myeloma Leuk. (2021) 21(10):e810&#x2013;6. doi: 10.1016/j.clml.2021.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2021.07.004</ArticleId><ArticleId IdType="pmc">PMC8286809</ArticleId><ArticleId IdType="pubmed">34393077</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CY, Shah MK, Hoyos D, Solovyov A, Douglas M, Taur Y, et al. . Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies. Cancer Discov (2021) 12(1):62&#x2013;73. doi: 10.1101/2021.08.25.21262417</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.08.25.21262417</ArticleId><ArticleId IdType="pmc">PMC8758535</ArticleId><ArticleId IdType="pubmed">34753749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hueso T, Pouderoux C, P&#xe9;r&#xe9; H, Beaumont AL, Raillon LA, Ader F, et al. . Convalescent plasma therapy for b-cell-depleted patients with protracted COVID-19. Blood (2020) 136(20):2290&#x2013;5. doi: 10.1182/blood.2020008423</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008423</ArticleId><ArticleId IdType="pmc">PMC7702482</ArticleId><ArticleId IdType="pubmed">32959052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcri C, Dentone C, Mikulska M, Bruzzone B, Lai A, Fenoglio D, et al. . The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient-a case study. Open Forum Infect Dis (2021) 8(11):ofab217. doi: 10.1093/ofid/ofab217</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab217</ArticleId><ArticleId IdType="pmc">PMC8135455</ArticleId><ArticleId IdType="pubmed">34796242</ArticleId></ArticleIdList></Reference><Reference><Citation>Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyuz N, et al. . Dynamic changes of the normal b lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. Oncoimmunology (2018) 7(4):e1417720. doi: 10.1080/2162402X.2017.1417720</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2017.1417720</ArticleId><ArticleId IdType="pmc">PMC5889203</ArticleId><ArticleId IdType="pubmed">29632735</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagacean C, Letestu R, Al-Nawakil C, Brichler S, L&#xe9;vy V, Sritharan N, et al. . Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia. Blood Adv (2022) 6(1):207&#x2013;11. doi: 10.1182/bloodadvances.2021006215</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021006215</ArticleId><ArticleId IdType="pmc">PMC8632355</ArticleId><ArticleId IdType="pubmed">34844264</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgogna C, Bruna R, Griffante G, Martuscelli L, De Andrea M, Ferrante D, et al. . Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients. Blood Cancer J (2022) 12(1):8. doi: 10.1038/s41408-022-00608-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-022-00608-6</ArticleId><ArticleId IdType="pmc">PMC8764505</ArticleId><ArticleId IdType="pubmed">35042847</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front Microbiol (2021) 12:698169. doi: 10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Sungnak W, Huang N, B&#xe9;cavin C, Berg M, Queen R, Litvinukova M, et al. . SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med (2020) 26(5):681&#x2013;7. doi: 10.1038/s41591-020-0868-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0868-6</ArticleId><ArticleId IdType="pmc">PMC8637938</ArticleId><ArticleId IdType="pubmed">32327758</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant RA, Morales-Nebreda L, Markov NS, Swaminathan S, Querrey M, Guzman ER, et al. . Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature (2021) 590(7847):635&#x2013;41. doi: 10.1038/s41586-020-03148-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03148-w</ArticleId><ArticleId IdType="pmc">PMC7987233</ArticleId><ArticleId IdType="pubmed">33429418</ArticleId></ArticleIdList></Reference><Reference><Citation>Truong TT, Ryutov A, Pandey U, Yee R, Goldberg L, Bhojwani D, et al. . Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series. EBioMedicine (2021) 67:103355. doi: 10.1016/j.ebiom.2021.103355</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103355</ArticleId><ArticleId IdType="pmc">PMC8072072</ArticleId><ArticleId IdType="pubmed">33915337</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussenblatt V, Roder AE, Das S, de Wit E, Youn JH, Banakis S, et al. . Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with b cell depletion. medRxiv [Preprint]. (2021) 5:2021.10.02.21264267. doi: 10.1101/2021.10.02.21264267</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.02.21264267</ArticleId><ArticleId IdType="pmc">PMC8755281</ArticleId><ArticleId IdType="pubmed">34940844</ArticleId></ArticleIdList></Reference><Reference><Citation>Pommeret F, Colomba J, Bigenwald C, Laparra A, Bockel S, Bayle A, et al. . Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with b-cell malignancies. Ann Oncol (2021) 32(11):1445&#x2013;7. doi: 10.1016/j.annonc.2021.07.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2021.07.015</ArticleId><ArticleId IdType="pmc">PMC8326208</ArticleId><ArticleId IdType="pubmed">34352377</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>